Shorter versus longer chemotherapy for stage II stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two lengths of an oral chemotherapy medicine (9 months vs 1 year) after surgery for stage II stomach cancer. It aims to see which schedule works better and is easier to complete, while checking safety for people without major health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 75.
- Your stomach cancer is confirmed as primary adenocarcinoma and is stage II based on pathology (exam of tissue).
- You already had surgery that fully removed the tumor (R0 resection) plus lymph node removal (D2 lymph node dissection).
- You do not have another active cancer and you have not had cancer other than this one.
- Your general health is good enough for chemotherapy (ECOG 0–1) and you’re expected to live more than 6 months.
- Your blood, liver, and kidney tests and heart tracing (ECG) are within acceptable ranges for chemotherapy (for example, enough white blood cells, platelets, and hemoglobin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving oxaliplatin for a shorter or longer time works best after curative surgery for stage II–III stomach (or stomach–esophagus junction) cancer. It aims to improve outcomes while balancing side effects from chemotherapy.
This trial is for people who have already had chemotherapy and surgery for stomach cancer. It compares different follow-up approaches to see if skipping more chemo after surgery is safe and effective.
This trial tests if giving a short course of radiation before surgery, along with standard chemotherapy, can help treat stomach cancer. It is for people newly diagnosed with stomach cancer who have not had treatment before.
This trial studies whether giving oxaliplatin plus S-1 (SOX) chemotherapy before stomach surgery works best when given for different cycle lengths. It may help shrink stage III gastric cancer before a standard D2 gastrectomy and improve outcomes.
This study compares two chemotherapy plans given before surgery for stage III stomach cancer (or the area where the esophagus meets the stomach). The goal is to see which approach works better to control the cancer and help people get the best surgical outcome.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.